Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
June 13, 2019 08:00 ET
|
Immutep Limited
Recruitment for 2nd line (PD-1 refractory) NSCLC and 2nd line HNSCC cohorts of the TACTI-002 trial, conducted in collaboration with MSD, are ongoingInitial data from the TACTI-002 study expected...
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
June 06, 2019 08:00 ET
|
Immutep Limited
Highlights First patient received first dose in INSIGHT-004, a phase I clinical trialEvaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indicationsPatient...
Immutep Presentation at ASCO 2019
June 03, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, June 03, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
May 23, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, May 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
May 17, 2019 08:00 ET
|
Immutep Limited
Presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 SYDNEY, Australia, May 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP)...
Immutep Announces Upcoming Industry Conference Participation
May 10, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, May 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
March 27, 2019 11:19 ET
|
Immutep Limited
SYDNEY, Australia, March 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
March 21, 2019 18:10 ET
|
Immutep Limited
SYDNEY, Australia, March 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep to Present IMP761 Preclinical Results in Global Webcast
March 18, 2019 19:07 ET
|
Immutep Limited
SYDNEY, Australia, March 18, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
March 07, 2019 16:30 ET
|
Immutep Limited
SYDNEY, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer...